SAB BIOTHERAPEUTICS, INC. Shareholders' Equity
SAB BIOTHERAPEUTICS, INC. (SABS) had Shareholders' Equity of $214.78 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $214.78M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $227.25M; Stockholders' Equity Attributable to Parent as first filed $227.25M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $151.50M; Stockholders' Equity Attributable to Parent as first filed $151.49M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $165.07M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $214.78M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $227.25M 10-Q · filed 2026-08-06 | $227.25M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $151.50M 10-Q · filed 2026-08-06 | $151.49M 10-K · filed 2026-03-09 |
| 2025-09-30 | $165.07M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $12.02M 10-Q · filed 2026-08-06 | $12.02M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $21.41M 10-Q · filed 2026-08-06 | $21.41M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $25.97M 10-Q · filed 2026-08-06 | $25.97M 10-K · filed 2025-03-31 |
| 2024-09-30 | $36.90M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $46.12M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $52.82M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $57.30M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $15.26M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $19.72M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $24.40M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $31.06M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $30.62M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $37.12M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $41.26M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $38.55M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $35.08M 10-Q · filed 2022-11-14 | -$9.29M 10-Q · filed 2021-11-22 |
| 2021-06-30 | $38.26M 10-Q · filed 2022-11-14 | $5.00M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $40.77M 10-Q · filed 2022-11-14 | $5.00M 10-Q · filed 2021-05-21 |
| 2021-01-14 | -$10.02M 10-Q · filed 2021-11-22 | $5.00M 10-Q · filed 2021-05-21 |
| 2020-12-31 | $39.01M 10-K/A · filed 2023-04-28 | $16.00K 10-K · filed 2021-04-02 |
| 2019-12-31 | $7.69M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |